the aadi bioscience conference call provides an operational update and review results for the second quarter 2023. we are pleased with our overall progress and we are truly excited about what lies ahead. we continue to enroll the preCISon 1 trial and are looking forward to sharing further information on our progress before the end of the year. we are excited about our new programs in endometrial cancer and neuroendocrine tumors and the prospects for our next-generation mTOR inhibitor in these indications with meaningful patient populations and high unmet need.